Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

Investors in Genmab A/S GMAB need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $17.50 Call had some of the highest implied volatility...

GMAB : 21.66 (-3.60%)
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...

NVO : 106.91 (-0.14%)
GMAB : 21.66 (-3.60%)
LLY : 811.81 (-0.86%)
ABBV : 170.35 (-0.43%)
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.ABBV...

NVO : 106.91 (-0.14%)
LLY : 811.81 (-0.86%)
ABBV : 170.35 (-0.43%)
GMAB : 21.66 (-3.60%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 26.72 (+2.02%)
ABBV : 170.35 (-0.43%)
JNJ : 153.24 (+0.39%)
RHHBY : 37.0200 (-0.88%)
GMAB : 21.66 (-3.60%)
AZN : 65.29 (+0.15%)
DSNKY : 29.8800 (-4.23%)
MRK : 98.50 (-0.08%)
LLY : 811.81 (-0.86%)
NVO : 106.91 (-0.14%)
Why Shares of Iovance Biotherapeutics Dropped Thursday

The biotech stock's lead therapy is looking at some competition.

SGEN : 228.74 (-0.07%)
GMAB : 21.66 (-3.60%)
IOVA : 9.00 (-7.12%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

ZLAB : 29.95 (+3.42%)
SGEN : 228.74 (-0.07%)
GMAB : 21.66 (-3.60%)
Is AbbVie Still a Good Dividend Stock to Buy?

Find out if AbbVie can overcome sinking sales of its top-selling product.

ABT : 115.74 (-0.60%)
RHHBY : 37.0200 (-0.88%)
AMGN : 301.44 (+0.87%)
GMAB : 21.66 (-3.60%)
ABBV : 170.35 (-0.43%)
3 Things About Johnson & Johnson Every Smart Investor Knows

The company has been a strong value stock but faces big changes this year.

KVUE : 23.14 (-1.30%)
AMGN : 301.44 (+0.87%)
GMAB : 21.66 (-3.60%)
JNJ : 153.24 (+0.39%)
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

ABBV : 170.35 (-0.43%)
GMAB : 21.66 (-3.60%)
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™...

ABBV : 170.35 (-0.43%)
GMAB : 21.66 (-3.60%)

Barchart Exclusives

3 Dividend Stocks to Scoop Up Now for a Strong 2025
With Donald Trump's return to the White House, the transportation industry could be set for big changes, and three dividend-paying stocks - J.B. Hunt, Knight-Swift, and CSX - are well-positioned to benefit from increased demand for shipping containers and freight services. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar